Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Parkinsonism & Related Disorders|September 17, 2008
Does melatonin help save dopaminergic cells in MPTP-treated mice?Jeannine Ma, Victoria E Shaw, John Mitrofanis
Parkinsonism & Related Disorders|March 16, 2010
Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleusVictoria E Shaw, Kevin A Keay, Keyoumars Ashkan, et al.
ISRN Neurology|June 16, 2012
Survival of Dopaminergic Amacrine Cells after Near-Infrared Light Treatment in MPTP-Treated MiceCassandra Peoples, Victoria E Shaw, Jonathan Stone, et al.
The Journal of Comparative Neurology|November 3, 2009
Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatmentVictoria E Shaw, Sharon Spana, Keyoumars Ashkan, et al.
Parkinson'S Disease|June 6, 2012
Patterns of Cell Activity in the Subthalamic Region Associated with the Neuroprotective Action of Near-Infrared Light Treatment in MPTP-Treated MiceVictoria E Shaw, Cassandra Peoples, Sharon Spana, et al.
Molecular Cancer|June 3, 2014
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic diseaseVictoria E Shaw, Brian Lane, Claire Jenkinson, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2013
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancerNicola E Annels, Victoria E Shaw, Rachel F Gabitass, et al.
Gut|January 15, 2016
Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microgliaIhsan Ekin Demir, Elke Tieftrunk, Stephan Schorn, et al.
Annals of Neurology|October 13, 2015
Near-infrared light is neuroprotective in a monkey model of Parkinson diseaseFannie Darlot, Cécile Moro, Nabil El Massri, et al.
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
Pageof 2